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One of the hallmarks of advanced malignancies is continuous cell growth and this almost universally correlates with the reactivation of
telomerase. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and
novel target for cancer therapeutics. Several clinical trials have been initiated, and in this review we highlight some of the most
promising approaches and conclude by speculating on the role of telomerase in cancer stem cells.
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Telomerase is a cellular reverse transcriptase (molecular motor)
that adds new DNA onto the telomeres that are located at the ends
of chromosomes (Collins and Mitchell, 2002). Telomeres consist of
long TTAGGG nucleotide repeats and an associated protein
complex, termed shelterin (de Lange, 2005). The shelterin complex
protects chromosome ends from end-to-end fusion and degrada-
tion forming special t-loop like structures and thus masking the
linear ends of chromosome from being recognised as single and/or
double-strand DNA breaks. The TTAGGG repeats shorten with
each cell division due to the end replication problem, oxidative
damage and other end processing events (Harley, 1991; Wright and
Shay, 2000). When a few telomeres become critically shortened
there is a growth arrest state, at which time a DNA damage signal
and cellular senescence are normally triggered (Shay, 2003). In the
absence of other changes, cells can remain in a quiescent/senescent
state for years and this can be thought of as a potent anticancer
protection mechanism for long-lived species such as humans.
However, human tumour cells derived from carcinomas almost
universally bypass cellular senescence and DNA damage-signalling
pathways. In cell line models, senescence bypass can be
accomplished by abrogating important cell-cycle checkpoint genes
(such as p53, p21, p16
INK4a and pRb), leading to extended growth
of the premalignant cells eventually leading to crisis (Wright et al,
1989). Crisis is a period where cell growth and death are in balance.
We believe that due to chromosome end fusions, there are
chromosome breakage-fusion-bridge events, leading to genomic
instability, rearrangements of chromosomes and eventually
activation or upregulation of telomerase. Telomerase is detected
in approximately 90% of all malignant tumours (Kim et al, 1994;
Shay and Bacchetti, 1997), making it a highly attractive target for
the development of mechanism-based therapeutics (Keith et al,
2007). The general schemes for targeting telomerase are well
described (Keith et al, 2004, 2007; Shay and Wright, 2006). This
review will therefore focus on discussing the most translational
approaches, which are in the final stages of preclinical develop-
ment and those that are already in clinical trials.
OVERVIEW OF APPROACHES TO TELOMERASE
THERAPEUTICS
Many investigators believe that targeting telomerase is a novel
approach to targeted cancer therapeutics. This is not without some
concerns, but in some instances therapy directed at telomerase has
advanced to clinical trials to validate safety, to obtain maximum
tolerable dose and in some cases to determine target specificity
(Keith and Bilsland, 2007). Although there are many potential ways
to interfere with normal telomerase function, only a few of the
most promising approaches in preclinical and clinical trials will be
described. Each approach has its own strengths and weaknesses
(see Table 1), many of which will only be resolved through clinical
Table 1 Summary of advantages and challenges to therapeutic
approaches to target telomerase cancer biology
Approach Advantages Challenges
Immunotherapy Broadly expressed tumour-
associated antigen
Cell death not subject to
phenotypic lag
Complex manufacture/
formulation
Complex biological
mechanism of action
Specialist clinical trial
expertise required
Gene therapy Highly tumour specific
Cell death not subject to
phenotypic lag
Complex manufacture/
formulation
Specialist clinical trial
expertise required
Small-molecule
oligonucleotides
Highly tumour specific
Clear clinical development
route
Synthetic routes for large-
scale production
Delayed death kill/
phenotypic lag Received 18 October 2007; revised 2 January 2008; accepted 3 January
2008; published online 29 January 2008
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Only through the inclusion of pharmacodynamic endpoints will
target specificity for telomerase be truly evaluated, and it is this
last point which will be the most challenging for trial development
(Keith et al, 2007).
There are three general classes of agents that have been
developed to target telomerase biology; gene therapy; immu-
notherapy and small-molecule inhibitors (Keith and Bilsland,
2007). In this review, we will consider some approaches that are
about to enter or have entered clinical trials, and include two gene
therapy approaches. The first approach uses either the proximal
hTERT (telomerase catalytic protein component) promoter to
make a general cancer-specific oncolytic virus or the hTR
promoter (template RNA component) to target a suicide gene
therapy vector. The more advanced clinical trials include a
telomerase-specific vaccine or immunotherapy; and the use of a
small molecule oligonucleotide therapy that acts as a telomerase
template antagonist. These approaches should not be seen as
competitive, as they each target a separate aspect of telomerase
cancer biology. No single trial will address all issues about how
telomerase therapeutics will behave in the human body. Rather,
progress in any one area will in part validate telomerase as a
clinically useful target.
CLINICAL DEVELOPMENT OF TELOMERASE
THERAPEUTICS
Gene therapy
No gene therapy product has yet been approved for the treatment
of cancer in Europe or USA, and considerable technical hurdles
remain to be resolved. However, there is a generally positive
attitude towards the concept of gene therapy as a selective
biological approach to treat cancer, and a belief within academia
and in at least some industrial sectors that this is a therapeutic
option that will eventually finds its place. However, this is
tempered by the predictions that this mode of therapy still
remains a long way from the market. More investment, develop-
ment work and technical innovation are required to provide
clinical validation of gene therapy, and telomerase may provide an
opportunity here (Keith and Bilsland, 2007).
The concept of targeting cancer cells with a telomerase inhibitor
assumes that an absence of telomerase will lead to a shortening of
the telomeres at every successive cell division. Over a number of
cell cycles, the chromosomes will become unstable and the cell will
no longer be viable. This will lead to cell death throughout the
tumour and the clinical effect will be tumour shrinkage (Keith
et al, 2007). An alternate approach to reduce the lag time is to
induce apoptotic pathways that can be coupled to telomerase
activity. For example, one could hijack a central control
mechanism that is responsible for regulating the expression of
telomerase in the cell, and use it to drive a suicide gene or
replication-competent adenovirus replication that will rapidly kill
the telomerase-expressing cancer cells (Keith et al, 2004).
There are two general approaches to telomerase gene therapy,
suicide gene therapy and oncolytic viral therapy. As a whole, the
preclinical studies of telomerase gene therapy have shown a
remarkable attention to specificity and efficacy using normal cells
strains and an extensive array of cancer models. Both the hTERT
and hTR promoters show promise in proof-of-concept studies in
both the oncolytic virus and suicide gene therapy settings, with
some minor concerns about off-target effects now emerging from
oncolytic virus studies (Keith et al, 2004, 2007; Cairney and Keith,
2008).
Ad-hTR-NTR: a telomerase-targeted adenoviral suicide gene
therapy vector There are three key components in the clinical
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Figure 1 Telomerase gene therapy approaches. Antisense gene therapy such as genetic approaches to target hTERT mRNA, siRNA-mediated inhibition
of a component of telomerase and so on, should selectively affect cells that are telomerase positive, while sparing telomerase-negative cells. This would be
expected to take a period of time before telomerase-expressing cells died. An approach that may speed up the efficacy of gene therapy involves targeting to
all cells a vector that encode an enzyme that when activated by a pro-drug will kill cells. The vector targeting telomerase is combined with an inactive enzyme
and when the pro-drug is added, a toxin is released that will only kill cells that are telomerase positive. The oncolytic viral therapy takes advantage of the idea
that upregulation or activation of the telomerase gene could enable the replication of a virus that could only replicate if telomerase is present. While this
could theoretically affect normal stem like cells expressing telomerase, it is not clear if this will be more toxic that standard chemotherapy that affect all
proliferating cells.
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suicide gene therapy construct; activation of the nitroreductase
enzyme (NTR) by the hTR promoter and the addition of the pro-
drug CB (Plumb et al, 2001; Bilsland et al, 2003). The telomerase
regulation of a suicide gene therapy approach is the novel
component of this therapeutic plan. The frequency of hTR
expression in cancers that result in advanced intra-abdominal
disease and ascites, the accessibility of these tumours both for
intra-peritoneal administration of Ad-hTR-NTR and for repeat
analysis of ascitic fluid for pharmacodynamic endpoints, means
that these tumours are a good test model for this ‘proof-of-
principle’ clinical trial of telomerase-specific suicide gene therapy.
In addition, the approach of using regional administration of virus
and pro-drug overcomes many of the limitations of direct intra-
tumoral injection, and the intention is to use this model system as
a step towards tackling the more fundamental issue of systemic
administration of these viruses.
Clinical study: A phase I study of Ad-hTR-NTR is due to start in
2008. This will be a single-dose, open-label, phase I study of
intraperitoneal Ad-hTR-NTR in patients with advanced inoperable
intra-abdominal cancer. This represents a number of different
primary tumour types, defined by their location in the abdomen
(including ovarian, colon, pancreatic and gastric), and also with
concomitant ascites (an accumulation of fluid in the abdominal
cavity). These tumour types are known to express significant levels
of hTR, and therefore expression of the suicide gene from the hTR
promoter should be strong. Because of the location and the
presence of ascites, there is considerable opportunity for retrieving
samples from the patient to monitor the progress of the therapy,
and this offers an opportunity to collect valuable information that
will contribute significantly to the further development of the
therapeutic regimen that would not be available in other cancer
models.
Telomerase-specific oncolytic virus This approach utilises adeno-
viruses that have been manipulated or engineered to have
oncolytic, or cancer-killing, properties, enabling them to selec-
tively target and destroy cancer cells that express telomerase
(Figure 1). The promoter region of the telomerase (hTERT) gene
regulating the replication of adenovirus does permit selective viral
propagation within cancer cells, but not normal cells that do not
express telomerase. Thus, telomerase-expressing tumour cells
containing the telomerase specific virus eventually rupture and
die, spreading to adjacent cells. When these same engineered
viruses infect normal somatic cells, there is no replication or
killing effects. This approach is known as a Tumour-specific
Replication-competent ADdenoviral (hTERTp-TRAD) gene ther-
apy approach (Keith et al, 2004, 2007).
This selective lytic effect on cancer has been demonstrated in
vitro in multiple tumour cell types, and has been extended to in
vivo animal models (Koga et al, 2001; Komata et al, 2001; Gu et al,
2002). Several groups have been advancing towards clinical trials,
but the work on Telomelysin, OBP-301 an attenuated adenovirus 5
vector in which the hTERT proximal promoter drives the
expression of E1A and E1B genes linked with an internal ribosome
entry site (Fujiwara et al, 2007), has recently advanced to clinical
trials. This approach was developed by T Fujiwara in collaboration
with Oncolys BioPharma Inc. (Minato-ku, Tokyo, Japan).
In collaboration with J Nemuniatis of the Mary Crowley Medical
Research Center (Dallas), the following clinical trial has recently
opened: MCMRC IRB#06–12; a Phase I Dose-Escalation Study of
Intratumoral Injection with Telomerase-Specific Replication-
Competent Oncolytic Adenovirus, Telomelysin (OBP-301), for
Various Solid Tumors (sponsor ID no. OBP-301-001). This is an
open-label, dose-escalation study in which a maximum of 24
subjects will be enrolled over three dose levels. Telomelysin will be
introduced intratumorally for local control in patients who have
failed typical local control radiation therapy. Another company,
Cell Genesys Inc., South San Francisco, CA, USA, is developing
CG5757, which is engineered with a secondary telomerase
promoter, employing technology licensed from Geron Corporation
(Menlo Park, CA, USA), but this has not yet advanced to clinical
trials.
Although this approach may be useful for local disease control,
systemic treatment has the potential for side effects on telomerase
competent proliferating cells. Immune cells that express telomer-
ase are not easily infected by adenovirus. However, systemic
hTERTp-TRAD might have some immediate side effects on
transient amplifying stem cells such as proliferating spermatocytes
in the testes, proliferating cells in the crypts of the intestine and a
subset of cells in the basal and suprabasal layer of the epidermis
(Wright et al, 1996). However, it is not certain if this approach will
be any more detrimental than conventional cytotoxic drugs that
affect all proliferating cells. The main problem may be that
intratumoral hTERTp-TRAD injections may be limited in the
ability of the adenoviral vectors to spread sufficiently and maintain
tumour burden reduction for any extended periods of time.
Telomerase (hTERT) immunotherapy
Telomerase may be a promising universal tumour antigen with
broad immunotherapeutic applicability to a wide range of distinct
cancers. hTERT protein is naturally processed and hTERT peptides
have been shown to be presented as epitopes by the MHC, eliciting
CTL responses and providing protective immunity against
tumours (Minev et al, 2000; Nair et al, 2000; Vonderheide et al,
2001; Vonderheide, 2002). There have been two general approaches
that have advanced to clinical trials.
Dendritic cell presentation approach Telomerase cancer vaccine
(GRNVAC1): In collaboration with the Geron Corporation,
investigators at Duke University Medical Center conducted a
phase I/II clinical trial on prostate cancer patients. The trial used
an ex vivo process where dendritic cells (the most efficient antigen-
presenting cells) were isolated from the patient’s blood, pulsed
with RNA for the telomerase protein component and then returned
to the patient’s body where they activated cytotoxic T cells to kill
tumour cells that expressed telomerase. The trial was designed to
enroll patients with metastatic prostate cancer, some who would
receive three weekly vaccinations (low-dose group), while the
remaining would receive six weekly vaccinations (high-dose
group). Twenty patients (12 of the low-dose group and eight of
the high-dose group) were enrolled and treated (Su et al, 2005).
None of the patients in either group had treatment-related adverse
effects. All but one of the patients in the low-dose group showed a
significant cellular immune response specific to telomerase. All
eight patients in the high-dose group showed robust cellular
immune responses to telomerase, on the basis of tests assessing the
generation of telomerase-specific cytotoxic CD8
þ T-lymphocytes,
as well as CD4
þ lymphocytes. The immune responses in the high-
dose group were strong as well as specific: peak responses were
1–2% of circulating CD8
þ T cells having anti-telomerase activity.
Levels of circulating cancer cells were also analysed. Ten subjects
had elevated levels of circulating prostate cancer cells before
vaccination. Nine of these 10 subjects had their levels reduced or
cleared transiently after vaccination. Serum PSA was measured
before, during and multiple times after vaccination to calculate
PSA doubling time as a surrogate marker for treatment response.
No significant change in PSA doubling time was observed in the
low-dose group. A highly significant increase in PSA doubling time
was observed in the high-dose group, suggestive of a clinical
response to vaccination. Geron has now entered into an agreement
with Merck & Co. Inc., Whitehouse Station, NJ, USA, for
manufacturing cancer vaccines targeting telomerase by methods
other than dendritic cell delivery.
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Hørsholm, Denmark, has developed an injectable formulation of
a promiscuous MHC class II peptide derived from the active site of
telomerase (hTERT), GV1001, for the treatment of pancreatic
(Bernhardt et al, 2006), liver and lung cancer (Brunsvig et al,
2006). After immunisation, the GV1001 peptide is processed and
presented as MHC class I epitopes. GV1001 induces CD4
þ and
CD8
þ T-cell immunity specific for hTERT. In phase I/II trials,
vaccination with GV1001 demonstrated hTERT-specific T-cell
responses with only minor associated side effects.
GV1001: A THERAPEUTIC VACCINE FOR
TREATMENT OF ADVANCED PANCREATIC CANCER
GV1001 exploits the fact that the immune system can actually
recognise and react to parts of the telomerase molecule when it is
presented in the right way. The GV1001 vaccine in a phase I/II
clinical trial was tested in 38 evaluable patients with pancreatic
cancer (Bernhardt et al, 2006). The patients were divided into three
dose groups: 60, 300 and 1000nmol. In the group of patients who
received the medium–high dose, 75% of the patients had an
immune response. The immune responses set in quickly, after 3–4
weeks, and was prolonged. The median lifetime of patients in the
medium-high dose group was 8.6 months, compared with a
median lifetime of approximately 5 months in patients treated with
gemcitabine chemotherapy. The difference in median lifetime
between immune responders and non-responders was 4.3 months.
GV1001 is currently being investigated in two large phase III trials
in pancreatic cancer. Together, the two trials, PrimoVax and
TeloVac, aim to test GV1001 in more than 1600 patients. The
PrimoVax trial is sponsored by Pharmexa and includes 520
pancreatic cancer patients from more than 80 centers in Europe,
USA and Australia. The TeloVac trial is an investigator-sponsored
trial designed and led by the National Cancer Research Institute in
England. The trial includes over 1100 pancreatic cancer patients
across UK.
GV1001: A THERAPEUTIC VACCINE AGAINST
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma, which can arise from cirrhosis and/or
infection with the hepatitis B or C viruses, causes approximately
600000 deaths annually. Treatment options for these patients are
limited. The HeptoVax trial (sponsored by Pharmexa) is ongoing
in Spain, France and Germany, and has enrolled approximately 50
patients with advanced hepatocellular carcinoma. Subjects are
receiving a single dose of cyclophosphamide 3 days before GV-
1001 vaccination. GV-1001 is then given with GM-CSF three times
in the first week, followed by one immunisation per week for 4
weeks. Booster immunisations are given once per month for a
minimum of 6 months.
In summary, while vaccinations in patients with high-grade
tumours have universally failed to provide a durable response,
preventative immunotherapy could be a viable option in patients
with surgically resectable tumour and perhaps in the future in
patients with a high risk for cancer development.
Targeting the RNA component of telomerase (telomerase
template antagonists)
GRN163L is a short-chain oligonucleotide that is unique in its
resistance to nuclease digestion in blood and tissues and its very
high affinity and specificity for telomerase (Dikmen et al, 2005;
Herbert et al, 2005; Gellert et al, 2006). The molecule has superior
cellular and tissue penetration properties due to the chemistry and
a5 0 lipid chain that facilitates entry into cells. GRN163L has
antitumour effects in a wide range of haematological and solid
tumour models and appears to be unique in its observed effects on
putative cancer initiating (stem like) cells – the rare, chemother-
apy-resistant cancer cells that are believed to cause cancer
recurrence.
On the basis of broad in vitro and in vivo proof of concept for
efficacy of telomerase inhibition in many major cancer types
tested, good safety profile and excellent pharmacokinetics and bio-
distribution, GRN163L has entered clinical trials (Geron Corpora-
tion). Initial trials as a single agent are ongoing in patients with
refractory or relapsed CLL and in patients with advanced solid
tumours (currently at 4.8mgkg
 1 per week). These early trials are
designed to determine safety and maximum tolerated doses.
GRN163L is a competitive substrate inhibitor with IC50 of
0.5–10nM, with recovery time for 50% telomerase activity being 9
days and a long T1
2 beta. This has led to weekly dosing in clinical trials.
More recently, a GRN163L phase I trial in stage IIIB and IV non-
small-cell lung cancer was initiated in combination with a standard
paclitaxel/carboplatin regimen (J Schiller, University of Texas
Southwestern Medical Center, Dallas). This is the first clinical trial
where GRN163L is being clinically tested in combination with
standard chemotherapy. While this is a phase I trial and cannot
formally address issues of combination, it begins to examine the
predicted mode of action of GRN163L. Preclinical data suggest
that in the presence of GRN163L, a period of time will be required
to shorten telomeres and thus GRN163L alone may or may not
provide rapid and durable responses (Figure 2A). However
combination of chemotherapy with a telomerase inhibitor should
result in an initial tumour burden reduction response to
chemotherapy, and over a period of weeks to months may result
in progressive telomere shortening and perhaps durable responses
(Figure 2A). In addition, there may be added benefits of the
telomerase inhibitors if cancer-initiating (stem like) cells are also
targeted. Additional trials on multiple myeloma as a single agent
and in combination with velcade will initiate in the near future,
and there is evidence that GRN163L may be active against
myeloma stem cells (W Matsui et al, unpublished data).
TELOMERASE AND CANCER STEM CELLS
Similar to normal stem cells, cancer stem (or initiating) cells also
have the ability to self-renew as well as undergo differentiation to
give rise to the phenotypically diverse types of cancer cells. If the
hypothesis is correct and only a rare subset of tumour stem cells
drives tumour formation, then the goal of cancer therapy should
be to identify this population of cells and to develop therapies
that target mechanisms that are more active in cancer stem cells,
sparing normal tissues. In the context of this review, it is
reasonable to ask if telomerase inhibitors not only target the bulk
of the tumour cell population, but also the rarer cancer stem cells
(Keith et al, 2007).
There are emerging data that suggest that normal stem cells may
have longer telomeres compared with cancer stem cells (JW Shay
et al, unpublished data), and thus there may be a window of
opportunity to target cancer stem cells by inhibiting telomerase
and driving telomeres short and cells into apoptotic cell death,
hopefully without irreversible damage to normal stem cells
(Figure 2B; Ponti et al, 2005; Drummond et al, 2007). The first
and perhaps key question is if cancer stem cells even express
telomerase activity. Interestingly, telomerase activity has been
detected in breast cancer stem cells, with some adult tissue stem
cells being telomerase negative (Ponti et al, 2005; Serakinci et al,
2006).
In addition, cancer cells cultured as spheroids on non-adherent
culture dishes have many stem cell markers (eg, Oct 4, Nanog,
SOX2) that are highly upregulated when compared with normal
adherent cancer cell cultures. When such human spheroids are
treated with GRN163L, we observe a decreased expression of these
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although cancer stem cells are maintained at low numbers in most
solid tumours, the treatment of human solid tumours with
telomerase inhibitors may shift the stem cell population from a
maintenance mode into a depletion mode, eventually leading to
loss of the putative stem cell population. In summary, telomerase
is a universal oncology target with high tumour specificity and
anti-telomerase therapies (such as GRN163L) may target the
cancer stem cell population as well as the bulk of the tumour
(Keith et al, 2007).
CONCLUSIONS/FUTURE PERSPECTIVES
It is encouraging to see that since the first demonstration of
widespread telomerase activity in tumours 13 years ago (Kim et al,
1994), drug development has been rapid, with several clinical trials
planned, in progress and completed. Future studies will build on
this firm foundation and should hopefully demonstrate clinical
value. Conventional drug development involves the assessment of
toxicity and pharmacokinetics (phase I), demonstration of activity
(phase II) and finally, comparison with existing standard practice
(phase III). It is likely that telomerase inhibitors will have the most
impact in minimal disease states such as in maintenance therapy
after tumour debulking by chemotherapy or in combination with
cytotoxic chemotherapy and phase III clinical trail design for
these settings is possible (Figure 3). Phase III trials in advanced
disease will address the questions of whether telomerase is an
active target in combination or after debulking chemotherapy
(Figure 3A), and if there will be an additive or synergistic effect
when a telomerase inhibitor is combined with chemotherapy
(Figure 3B). At the present time, it is unknown what the most
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Figure 3 Clinical trial design for telomerase inhibitors. (A) A proposed phase III clinical trial design of telomerase inhibitors as maintenance therapy. This
situation may be applicable to small-cell lung cancer after debulking chemotherapy. (B) A proposed phase III clinical trial design of telomerase inhibitors in
combination with cytotoxic chemotherapy. The main endpoints are progression-free survival and overall survival.
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Figure 2 (A) Conventional vs combinatorial therapy. With standard chemotherapy, tumour burden can initially result in a partial tumour reduction
response, but almost universally a subset of resistant cells results in recurrence of disease. Thus, standard chemotherapy that does not affect telomere length
will results in recurrence of disease with a similar average telomere length (eg, 7kb). In contrast, combining chemotherapy with telomerase inhibitors should
results in both a partial response and a gradual shortening of telomeres (right side of figure). There is every indication on the basis of preclinical research that
small oligonucleotide readily enter all cancer cells. The hope is that both sensitive and chemotherapy-resistant cells may shorten their telomeres, eventually
leading to more durable responses. (B) Telomerase inhibitors affect stem cells and cancer cell differently. It has been reported (unpublished results) using
markers of cancer stem cells that telomeres are shorter compared with normal stem cells. Thus, there should be a window of opportunity to target cancer
stem cells with short telomeres using telomerase inhibitors, leading to cancer stem cell depletion before normal stem cells become critically shortened.
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with established therapies. However, the emerging data from the
early clinical trials will aid this stage of development. Possibilities
may also exist for using telomerase inhibitors as adjuvant therapy
in early disease or even chemoprevention studies. The scope for
innovative clinical trial design and application is also increased
through biotherapeutic approaches in immunotherapy and gene
therapy.
However, although the speed at which trials have emerged is
promising, there are few published biomarker studies to show that
the anti-telomerase therapeutic is indeed interacting with the
target as predicted. Like all mechanism-based therapeutics,
telomerase inhibitors need to show clinical proof of concept. The
laboratory tools, reagents and assays are available to support trial
activity. Importantly, by making full use of innovative trial design,
not only will the next generation of targeted therapeutics be
developed, but there will also be progress in our understanding of
the basic biology of human telomerase necessary to drive future
waves of telomerase research.
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